SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SEATTLE, May 31, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Jefferies 2017 Healthcare Conference in New York on Tuesday, June 6, 2017, at 8:00 a.m. Eastern time / 5:00 a.m. Pacific time.
A live audio webcast of the presentation will be available through the “Events & Presentations” page of the “News & Events” section of Cascadian Therapeutics’ website at www.cascadianrx.com. An archived edition of the session will be available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib (also known as ONT-380) is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.
Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected]
